- Featured Product
- KD/KO Validated
MEK4 Polyclonal Antibody for IHC, WB, ELISA
Cat no : 17340-1-AP
JNK activating kinase 1, JNKK, JNKK1, MAP kinase kinase 4, MAP2K4, MAPK/ERK kinase 4, MAPKK 4, MAPKK4, MEK 4, MEK4, MKK4, PRKMK4, SAPK/ERK kinase 1, SEK1, SERK1
|Positive WB detected in||HeLa cells, MCF-7 cells, RAW264.7|
|Positive IHC detected in||human breast cancer tissue, human liver cancer tissue, human skeletal muscle tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:500-1:2000|
|Immunohistochemistry (IHC)||IHC : 1:20-1:200|
|Sample-dependent, check data in validation data gallery|
The 17340-1-AP immunogen is Fusion Protein MEK4 protein expressed in E. coli.
|Tested Reactivity||human, mouse, rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||MEK4 fusion protein Ag11376|
|Full Name||mitogen-activated protein kinase kinase 4|
|Calculated molecular weight||399aa,44 kDa|
|Observed molecular weight||44-46 kDa|
|GenBank accession number||BC036032|
|Gene ID (NCBI)||6416|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.1% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
MEK4 is also named as JNKK1, MAP2K4 , MKK4, PRKMK4, SEK1, SERK1, SKK1 and belongs to the protein kinase superfamily. MEK4 is a member of the mitogen-activated protein kinase family, originally identified as a kinase involved in the stress-activated protein kinase pathway by directly phosphorylating c-Jun NH 2-terminal kinase. This protein has 2 isoforms produced by alternative splicing.
Cinobufotalin powerfully reversed EBV-miR-BART22-induced cisplatin resistance via stimulating MAP2K4 to antagonize non-muscle myosin heavy chain IIA/glycogen synthase 3β/β-catenin signaling pathway.
Dig Dis Sci
LPS Induced miR-181a Promotes Pancreatic Cancer Cell Migration via Targeting PTEN and MAP2K4.
Int J Biochem Cell Biol
Androgen-induced miR-27A acted as a tumor suppressor by targeting MAP2K4 and mediated prostate cancer progression.